|
|
||||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLES |
Department of Health Sciences, University IUSM of Rome, Italy
Correspondence to:
Professor C Baldari, Istituto Universitario di Scienze Motorie (IUSM), Piazza Lauro De Bosis, 15, 00194 Roma, Italy; carlo.baldari{at}iusm.it
Objective: Given the therapeutic and non-therapeutic use of the tadalafil, (phosphodiesterase-5 inhibitor, PDE-5i), we examined its effects on anaerobic performance indices.
Methods: In total, 12 well-trained subjects reported to the laboratory on two occasions 1 week apart to perform a 30 s Wingate anaerobic power test (WAnT) on a bicycle ergometer. The day before the WAnT, the subjects were double-blinded to receive an oral dose of tadalafil (20 mg) or placebo. Blood lactate value at rest and 1, 3, 6 and 10 minutes of recovery phase, mean power, peak power, time to peak power and fatigue index were assessed for each WAnT.
Results: Blood lactate values at the 3-min recovery WAnT increased significantly in the tadalafil condition (mean (SD) 13.9 (1.7) v 12.8 (1.3) mmol/l; p<0.05) and time to peak power decreased significantly (6.3 (1.3) v 5.7 (1.5) s; p = 0.05). No differences were observed in any other parameters between the two conditions.
Conclusion: The primary finding of this investigation was that the administration of a single dose of a long-term PDE-5i does not substantially influence anaerobic performance indices. However, results demonstrated both an increase in lactate values at the 3-min point of the recovery phase and a decrease in time to peak power.
Keywords: PDE-5i; erectile dysfunction; sport; nitric oxide
This article has been cited by other articles:
![]() |
L. Di Luigi, C. Baldari, P. Sgro, G. P. Emerenziani, M. C. Gallotta, S. Bianchini, F. Romanelli, F. Pigozzi, A. Lenzi, and L. Guidetti The Type 5 Phosphodiesterase Inhibitor Tadalafil Influences Salivary Cortisol, Testosterone, and Dehydroepiandrosterone Sulphate Responses to Maximal Exercise in Healthy Men J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3510 - 3514. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |